Drug Approval | February 18, 2023
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Themis will market this drug with the brand name REMITHEM.
Themis will market this drug with the brand name REMITHEM.
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA
he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
The drug is indicated for use in combination with other drugs
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Subscribe To Our Newsletter & Stay Updated
